Affini-T Therapeutics | Unlocking the power of T cells

Affini-T is developing specific TCR-based immunotherapies for solid tumors using two complementary therapeutic modalities

Affini T Left

Affini T Middle

Affini T Right

Latest News

03.13.2024

Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting

Press Releases

01.07.2024

Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Press Releases

11.13.2023

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

Press Releases

10.31.2023

Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Press Releases

Read More